Errasti, AM, Soto-Cambres, AM, Mitre, SJR, Ni o, LM, Calvet, G, Perez-Montero, H, Pardo, GS. Impact of dose escalation on positive nodes in prostate cancer patients with pelvic nodal disease. RADIOTHERAPY AND ONCOLOGY. 2024; 194DOI:. PMID:. IF:5.300(Q1/2D).

Najjari-Jamal, D, Cordoba-Largo, S, Rovirosa, A, Sanchez-Belda, M, Majercakova, K, Garcia-Cabezas, S, Gimeno-Morales, M, Guevara-Barrera, D, Mu oz, T, De La Fuente, C, Mico, S, Matute, R. IS REIRRADIATION IN GYNAECOLOGICAL CANCER A REALITY? : A NATIONAL (SPANISH) SURVEY. RADIOTHERAPY AND ONCOLOGY. 2024; 194DOI:. PMID:. IF:5.300(Q1/2D).

Ans n, C, Carrasco, P, Bermejo, S, Jimenez, J, Ventosa, N, Balart, J, Jornet, N, Gallego, P, P rez-Alija, J, Tejedor, N, Vivancos, H, Ruiz, A, Barcel , M, Leo, F, Dom nguez, A, Riu, V, Sancho, G. EBH abdominal SBRT: inter- and intrafraction motion using two commercial monitoring systems. RADIOTHERAPY AND ONCOLOGY. 2024; 194DOI:. PMID:. IF:5.300(Q1/2D).

Bermejo, S, Ans n, C, Carrasco, P, Jim nez, J, Ventosa, N, de Segura, GG, Balart, J, Otero, E, Vizuete, A, Domenech, J, Suri ach, F, Soto, A, Farr , N, Jornet, N, Sancho, G. Impact of coaching reinforcement on SGRT-guided abdominal SBRT with expiration breath-hold (EBH). RADIOTHERAPY AND ONCOLOGY. 2024; 194DOI:. PMID:. IF:5.300(Q1/2D).

Montezuma, L, Leon-Vintr , X, Majerc kov , K, Juli , J, Farr , N, Rojas, J, Rabi, S, Crespo, S, Calvet, G, Camacho, M, Sancho, G. Prognostic ability of TGF-ß and IL-6 in patients with HNSCC treated with RT. RADIOTHERAPY AND ONCOLOGY. 2024; 194DOI:. PMID:. IF:5.300(Q1/2D).

Pla, EO, Cambres, AMS, Franco, PG, Sala, NJ, Rabi, S, P rez, SMC, Molinas, GC, Beltr n, JS, Recio, SM, Mart nez, SB, Pardo, GS, Bernad , NF. Clinical and dosimetric predictors of cardiotoxicity for locally advanced lung cancer. RADIOTHERAPY AND ONCOLOGY. 2024; 194DOI:. PMID:. IF:5.300(Q1/2D).